← All trials
NCT04626583
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 15, 2021
- Primary completion
- Jun 30, 2021
- Completion date
- Dec 30, 2023
- First posted
- Nov 12, 2020
- Last posted
- Dec 11, 2020
- Enrollment
- 18
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of Illinois at ChicagoLead sponsor
- University of Illinois at ChicagoOverall official - principal investigator
- University of Illinois at ChicagoReponsible party - principal investigator
- Department of DefenseCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.